<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01525225</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-153</org_study_id>
    <nct_id>NCT01525225</nct_id>
  </id_info>
  <brief_title>Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM</brief_title>
  <official_title>Evaluation of the Pharmacokinetics of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin in Children and Adolescents Aged 10 to 17 Years With Type 2 Diabetes Mellitus Following Oral Administration of Saxagliptin and Metformin XR Fixed Dose Combination Tablet and Co-Administration of Saxagliptin and Glucophage® (Metformin) IR Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy
      Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM)
      following oral administration of Saxagliptin and Metformin XR fixed dose combination tablet
      and co-administration of Saxagliptin and Glucophage® (Metformin) IR tablets
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose is to assess the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin,
      and Metformin in pediatric subjects aged 10 to 17 years with T2DM following oral
      administration of Saxagliptin and Metformin XR fixed dose combination tablet and
      co-administration of Saxagliptin and Glucophage® (Metformin) IR tablets
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Release of Post Marketing Requirement for this study. Terminated November 2013.
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death</measure>
    <time_frame>Day 1 up to Day 8, plus 30 days</time_frame>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities</measure>
    <time_frame>Day 1 to Day 8</time_frame>
    <description>Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:&gt;1.25*Pre-RX if Pre-RX &gt;ULN or &gt;1.25*ULN if Pre-RX &lt;=ULN; aspartate aminotransferase U/L: &gt;1.25*Pre-RX if Pre-RX&gt;ULN or 1.25*ULN if Pre-RX&lt;=ULN;alanine aminotransferase U/L: &gt;1.25*Pre-RX if Pre-RX&gt;ULN or 1.25*ULN if Pre-RX&lt;=ULN;blood urea nitrogen mmol/L: &gt;1.1*ULN if Pre-RX &lt;=ULN or &gt;1.2*Pre-RX if Pre-RX &gt;ULN; total bilirubin µmol/L: &gt;1.1*ULN if Pre-RX &lt;=ULN or &gt;1.25*Pre-RX if Pre-RX &gt;ULN; creatine phosphokinase U/L: &gt;1.5*Pre-RX if Pre-RX&gt;ULN or &gt;1.5*ULN if Pre-RX &lt;= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): &lt;0.85* pre-RX; hematocrit (%): &lt;0.85*pre-RX;erythrocytes (*10^12 c/L): &lt;0.85*pre-RX; platelet count (*10^9 c/L): &lt;0.85*LLN if pre-RX&gt;=LLN, or if Pre-Tx &lt;LLN; leukocytes (*10^9 c/L): &lt;0.85*LLN if pre-RX &lt;LLN,or &lt;0.9*LLN if LLN&lt;=Pre-RX&lt;=ULN.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin immediate release (IR)</intervention_name>
    <description>Tablet, Oral, 1000 mg, twice daily, 1 day</description>
    <arm_group_label>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</arm_group_label>
    <other_name>Glucophage® IR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <description>Tablet, Oral, 5 mg, single-dose, 1 day</description>
    <arm_group_label>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin IR</intervention_name>
    <description>Tablet, Oral, 1000 mg, twice daily, 5 days</description>
    <arm_group_label>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</arm_group_label>
    <other_name>Glucophage® IR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin/Metformin XR FDC</intervention_name>
    <description>Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).</description>
    <arm_group_label>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR</intervention_name>
    <description>Tablet, Oral, 500 mg, Single-dose of 4 tablets</description>
    <arm_group_label>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</arm_group_label>
    <other_name>Glucophage® XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of T2DM

          -  Male and female subjects ages 10-17

          -  Body weight ≥50 kg

          -  Glycosylated hemoglobin (HbA1c) 6.5 to 10%

        Exclusion Criteria:

          -  Fasting plasma glucose (FPG) &gt; 240 mg/dL at screening

          -  Abnormal renal function

          -  Active liver disease and/or significant abnormal liver function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osborne Research Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children'S Mercy Hospital And Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Promedica Toledo Children'S Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Promedica Toledo Childrens Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Of Pittsburgh Of Upmc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <results_first_submitted>August 11, 2014</results_first_submitted>
  <results_first_submitted_qc>August 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2014</results_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Upon approval of Kombiglyze™ XR, the Food and Drug Administration (FDA) required the conduct of this clinical pharmacology study in pediatric patients as a post-marketing requirement (PMR). Study was initiated February 2013. On 14-Nov-13, the FDA issued a letter stating release from this PMR, thus the study was terminated prior to completion.</recruitment_details>
      <pre_assignment_details>A total of 4 participants were enrolled. Two participants were treated and completed the study prior to the termination of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</title>
          <description>Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage® immediate release (IR) tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage® IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin extended release (XR) fixed dose combination (FDC) tablets. Finally, on Day 8 participants received four 500 mg Glucophage® IR tablets QD. All study drugs were administered with food.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Enrollment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No longer met study criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treated</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</title>
          <description>Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage® IR tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage® IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin XR FDC tablets. Finally, on Day 8 participants received four 500 mg Glucophage® IR tablets QD. All study drugs were administered with food.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.0" lower_limit="10.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
        <time_frame>Day 1 up to Day 8, plus 30 days</time_frame>
        <population>All participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</title>
            <description>Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage® IR tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage® IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin XR FDC tablets. Finally, on Day 8 participants received four 500 mg Glucophage® IR tablets QD. All study drugs were administered with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) , Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Death</title>
          <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
          <population>All participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-Related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE Leading to Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities</title>
        <description>Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:&gt;1.25*Pre-RX if Pre-RX &gt;ULN or &gt;1.25*ULN if Pre-RX &lt;=ULN; aspartate aminotransferase U/L: &gt;1.25*Pre-RX if Pre-RX&gt;ULN or 1.25*ULN if Pre-RX&lt;=ULN;alanine aminotransferase U/L: &gt;1.25*Pre-RX if Pre-RX&gt;ULN or 1.25*ULN if Pre-RX&lt;=ULN;blood urea nitrogen mmol/L: &gt;1.1*ULN if Pre-RX &lt;=ULN or &gt;1.2*Pre-RX if Pre-RX &gt;ULN; total bilirubin µmol/L: &gt;1.1*ULN if Pre-RX &lt;=ULN or &gt;1.25*Pre-RX if Pre-RX &gt;ULN; creatine phosphokinase U/L: &gt;1.5*Pre-RX if Pre-RX&gt;ULN or &gt;1.5*ULN if Pre-RX &lt;= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): &lt;0.85* pre-RX; hematocrit (%): &lt;0.85*pre-RX;erythrocytes (*10^12 c/L): &lt;0.85*pre-RX; platelet count (*10^9 c/L): &lt;0.85*LLN if pre-RX&gt;=LLN, or if Pre-Tx &lt;LLN; leukocytes (*10^9 c/L): &lt;0.85*LLN if pre-RX &lt;LLN,or &lt;0.9*LLN if LLN&lt;=Pre-RX&lt;=ULN.</description>
        <time_frame>Day 1 to Day 8</time_frame>
        <population>Participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</title>
            <description>Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage® IR tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage® IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin XR FDC tablets. Finally, on Day 8 participants received four 500 mg Glucophage® IR tablets QD. All study drugs were administered with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Marked Chemistry or Hematology Laboratory Abnormalities</title>
          <description>Lower limit of normal (LLN); upper limit of normal (ULN); treatment (RX); pre-treatment (Pre-Rx); units per liter (U/L); millimoles per liter (mmol/L). Alkaline phosphatase U/L:&gt;1.25*Pre-RX if Pre-RX &gt;ULN or &gt;1.25*ULN if Pre-RX &lt;=ULN; aspartate aminotransferase U/L: &gt;1.25*Pre-RX if Pre-RX&gt;ULN or 1.25*ULN if Pre-RX&lt;=ULN;alanine aminotransferase U/L: &gt;1.25*Pre-RX if Pre-RX&gt;ULN or 1.25*ULN if Pre-RX&lt;=ULN;blood urea nitrogen mmol/L: &gt;1.1*ULN if Pre-RX &lt;=ULN or &gt;1.2*Pre-RX if Pre-RX &gt;ULN; total bilirubin µmol/L: &gt;1.1*ULN if Pre-RX &lt;=ULN or &gt;1.25*Pre-RX if Pre-RX &gt;ULN; creatine phosphokinase U/L: &gt;1.5*Pre-RX if Pre-RX&gt;ULN or &gt;1.5*ULN if Pre-RX &lt;= ULN. Grams per liter (g/L); cells per liter (c/L). Hemoglobin (g/L): &lt;0.85* pre-RX; hematocrit (%): &lt;0.85*pre-RX;erythrocytes (*10^12 c/L): &lt;0.85*pre-RX; platelet count (*10^9 c/L): &lt;0.85*LLN if pre-RX&gt;=LLN, or if Pre-Tx &lt;LLN; leukocytes (*10^9 c/L): &lt;0.85*LLN if pre-RX &lt;LLN,or &lt;0.9*LLN if LLN&lt;=Pre-RX&lt;=ULN.</description>
          <population>Participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to Day 8, plus 30 days.</time_frame>
      <desc>Study initiated February 2013 and was terminated November 2013. Last patient, last visit was June 2013.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC</title>
          <description>Each participant received one dose of a 5 mg saxagliptin tablet once a day (QD) and a 1000 mg Glucophage® IR tablet twice a day (BID) on Day 1. On Days 2 through 6, participants received a 1000 mg tablet of Glucophage® IR BID, and on Day 7, participants received one dose of two 2.5 mg saxagliptin/1000 mg metformin XR FDC tablets. Finally, on Day 8 participants received four 500 mg Glucophage® IR tablets QD. All study drugs were administered with food.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the small number of participants (2), the primary endpoints, pharmacokinetic parameters, were not calculated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

